Improved outcome after relapse in children with acute myeloid leukaemia

British Journal of Haematology

Volumn 136, Issue 2, 2007, Pages 229-236

  Abrahamsson, Jonas ^a,i   Clausen, Niels ^b   Gustafsson, Göran ^c   Hovi, Liisa ^d   Jonmundsson, Gudmundur ^e   Zeller, Bernward ^f   Forestier, Erik ^g   Heldrup, Jesper ^h   Hasle, Henrik ^b  

^a Queen Silvias Childrens Hospital   (Sweden)

^b AARHUS UNIVERSITY   (Denmark)

^c KAROLINSKA INSTITUTE   (Sweden)

^d UNIVERSITY OF HELSINKI   (Finland)

^e LANDSPITALI UNIVERSITY HOSPITAL   (Iceland)

^f OSLO UNIVERSITY HOSPITAL   (Norway)

^g UMEÅ UNIVERSITY   (Sweden)

^h LUND UNIVERSITY HOSPITAL   (Sweden)

ⁱ QUEEN SILVIA CHILDREN'S HOSPITAL   (Sweden)

Author keywords

Acute myeloid leukaemia; Chemotherapy; Children; Relapse; Stem cell transplantation

Indexed keywords

AMSACRINE; CYTARABINE; DAUNORUBICIN; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IDARUBICIN; MITOXANTRONE; RETINOIC ACID; TIOGUANINE;

ACUTE GRANULOCYTIC LEUKEMIA; ADD ON THERAPY; ADOLESCENT; ARTICLE; CANCER CHEMOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; CANCER THERAPY; CONTROLLED STUDY; DRUG FATALITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; REMISSION; STEM CELL TRANSPLANTATION; SURVIVAL RATE;

ACUTE DISEASE; ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CYTARABINE; CYTOGENETICS; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; LEUKEMIA, MYELOID; MALE; RECURRENCE; REMISSION INDUCTION; STATISTICS, NONPARAMETRIC; STEM CELL TRANSPLANTATION; SURVIVAL RATE; SWEDEN; TREATMENT OUTCOME; VIDARABINE;

EID: 33845874653     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2006.06419.x     Document Type: Article

References (19)

1. Aladjidi, N., Auvrignon, A., Leblanc, T., Perel, Y., Benard, A., Bordigoni, P., Gandemer, V., Thuret, I., Dalle, J.H., Piguet, C., Pautard, B., Baruchel, A. & Leverger, G. (2003) Outcome in children with relapsed acute myeloid leukemia after initial treatment with the French Leucemie Aique Myeloide Enfant (LAME) 89/91 protocol of the French Society of Pediatric Hematology and Immunology. Journal of Clinical Oncology, 21, 4377-4385.
2. Choi, S.J., Lee, J.H., Lee, J.H., Kim, S., Seol, M., Lee, Y.S., Lee, J.S., Kim, W.K., Chi, H.S. & Lee, K.H. (2004) Treatment of relapsed acute myeloid leukemia after allogeneic bone marrow transplantation with chemotherapy followed by G-CSF-primed donor leukocyte infusion: a high incidence of isolated extramedullary relapse. Leukemia, 18, 1789-1797.
3. Collins, Jr, R.H. , Shpilberg, O., Drobyski, W.R., Porter, D.L., Giralt, S., Champlin, R., Goodman, S.A., Wolff, S.N., Hu, W., Verfaillie, C., List, A., Dalton, W., Ognoskie, N., Chetrit, A., Antin, J.H. & Nemunaitis, J. (1997) Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. Journal of Clinical Oncology, 15, 433-444.
4. Craddock, C., Tauro, S., Moss, P. & Grimwade, D. (2005) Biology and management of relapsed acute myeloid leukaemia. British Journal of Haematology, 129, 18-34.
5. 2 idarubicin during induction: results of a pilot study in children with AML. Leukemia, 14, 340-342.
6. Creutzig, U., Zimmermann, M., Ritter, J., Reinhardt, D., Hermann, J., Henze, G., Jurgens, H., Kabisch, H., Reiter, A., Riehm, H., Gadner, H. & Schellong, G. (2005) Treatment strategies and long-term results in paediatric patients treated in four consecutive AML-BFM trials. Leukemia, 19, 2030-2042.
7. Eapen, M., Giralt, S.A., Horowitz, M.M., Klein, J.P., Wagner, J.E., Zhang, M.J., Tallman, M.S., Marks, D.I., Camitta, B.M., Champlin, R.E., Ringden, O., Bredeson, C.N., Martino, R., Gale, R.P., Cairo, M.S., Litzow, M.R. & de Lima, M. (2004) Second transplant for acute and chronic leukemia relapsing after first HLA-identical sibling transplant. Bone Marrow Transplantation, 34, 721-727.
8. Gibson, B.E., Wheatley, K., Hann, I.M., Stevens, R.F., Webb, D., Hills, R.K., De Graaf, S.S. & Harrison, C.J. (2005) Treatment strategy and long-term results in paediatric patients treated in consecutive UK AML trials. Leukemia, 19, 2130-2138.
9. Kaspers, G.J. & Creutzig, U. (2005) Pediatric acute myeloid leukemia: international progress and future directions. Leukemia, 19, 2025-2029.
10. Kern, W., Schoch, C., Haferlach, T., Braess, J., Unterhalt, M., Wormann, B., Buchner, T. & Hiddemann, W. (2000) Multivariate analysis of prognostic factors in patients with refractory and relapsed acute myeloid leukemia undergoing sequential high-dose cytosine arabinoside and mitoxantrone (S-HAM) salvage therapy: relevance of cytogenetic abnormalities. Leukemia, 14, 226-231.
11. Lie, S.O., Abrahamsson, J., Clausen, N., Forestier, E., Hasle, H., Hovi, L., Jonmundsson, G., Mellander, L. & Gustafsson, G. (2003) Treatment stratification based on initial in vivo response in acute myeloid leukaemia in children without Down's syndrome: results of NOPHO-AML trials. British Journal of Haematology, 122, 217-225.
12. Lie, S.O., Abrahamsson, J., Clausen, N., Forestier, E., Hasle, H., Hovi, L., Jonmundsson, G., Mellander, L., Siimes, M.A., Yssing, M., Zeller, B. & Gustafsson, G. (2005) Long-term results in children with AML: NOPHO-AML Study Group-report of three consecutive trials. Leukemia, 19, 2090-2100.
13. McCarthy, A.J., Pitcher, L.A., Hann, I.M. & Oakhill, A. (1999) FLAG (fludarabine, high-dose cytarabine, and G-CSF) for refractory and high-risk relapsed acute leukemia in children. Medical and Pediatric Oncology, 32, 411-415.
14. Perel, Y., Auvrignon, A., Leblanc, T., Vannier, J.P., Michel, G., Nelken, B., Gandemer, V., Schmitt, C., Lamagnere, J.P., De Lumley, L., Bader-Meunier, B., Couillaud, G., Schaison, G., Landman-Parker, J., Thuret, I., Dalle, J.H., Baruchel, A. & Leverger, G. (2002) Impact of addition of maintenance therapy to intensive induction and consolidation chemotherapy for childhood acute myeloblastic leukemia: results of a prospective randomized trial, LAME 89/91. Leucamie Aique Myeloide Enfant. Journal of Clinical Oncology, 20, 2774-2782.
15. Perel, Y., Auvrignon, A., Leblanc, T., Michel, G., Reguerre, Y., Vannier, J.P., Dalle, J.H., Gandemer, V., Schmitt, C., Mechinaud, F., Lejars, O., Piguet, C., Couillaud, G., Pautard, B., Landman-Parker, J., Thuret, I., Aladjidi, N., Baruchel, A. & Leverger, G. (2005) Treatment of childhood acute myeloblastic leukemia: dose intensification improves outcome and maintenance therapy is of no benefit-multicenter studies of the French LAME (Leucemie Aigue Myeloblastique Enfant) Cooperative Group. Leukemia, 19, 2082-2089.
16. Saarinen-Pihkala, U.M., Gustafsson, G., Ringden, O., Heilmann, C., Glomstein, A., Lonnerholm, G., Abrahamsson, J., Bekassy, A.N., Schroeder, H. & Mellander, L. (2001) No disadvantage in outcome of using matched unrelated donors as compared with matched sibling donors for bone marrow transplantation in children with acute lymphoblastic leukemia in second remission. Journal of Clinical Oncology, 19, 3406-3414.
17. Stahnke, K., Boos, J., Bender-Gotze, C., Ritter, J., Zimmermann, M. & Creutzig, U. (1998) Duration of first remission predicts remission rates and long-term survival in children with relapsed acute myelogenous leukemia. Leukemia, 12, 1534-1538.
18. Styczynski, J. & Wysocki, M. (2004) Ex vivo drug resistance in childhood acute myeloid leukemia on relapse is not higher than at first diagnosis. Pediatric Blood and Cancer, 42, 195-199.
19. Webb, D.K., Wheatley, K., Harrison, G., Stevens, R.F. & Hann, I.M. (1999) Outcome for children with relapsed acute myeloid leukaemia following initial therapy in the Medical Research Council (MRC) AML 10 trial. MRC Childhood Leukaemia Working Party. Leukemia, 13, 25-31.